본문 바로가기
KERD
논문KCI 등재

음성 증상이 주된 조현병 환자에서 Aripiprazole의 효과에 대한 52주의 전향적 연구

Efficacy of Aripiprazole in Korean Schizophrenic Patients with Prominent Negative Symptoms : A 52-Week, Prospective, Open-Label Study

권준수|김혜수|김성년|장준환
대한생물치료정신의학회 (Korean Society Of Biological Therapies In Psychiatry)|2011.12|생물치료정신의학 (Journal of the Korean Society of Biological Therapies in Psychiatry)|제17권 제2호|pp. 267-274

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

아리피프라졸·조현병·음성 증상·효능·장기간 치료Aripiprazole · Schizophrenia · Negative symptoms · Efficacy · Long-term treatment
주제분류정신과학

초록

본 연구는 aripiprazole이 만성 조현병 환자의 선택 약제로 사용될 수 있는 작은 가능성을 제시하였다고 평가할 수 있겠다. 많은 종류의 항정신병약물이 조현병의 치료를 위해 쓰여지고 있는 현 상황에서, 병의 경과 상 다양한 시점에 놓인 각각의 환자군에 대한 보다 많은 종류의 항정신병약물 효과에 대한 비교 연구가 축적된다면, 임상의사의 약물 선택에 대한 시행착오가 지금보다는 줄 어들 수 있을 것이다.

Abstract

Objectives：This study was done to evaluate the efficacy of aripiprazole in the schizophrenic patients with prominent negative symptoms. Methods：This study was a prospective, multicenter, single-group, 52-week open study of patients with schizophrenia, schizophreniform disorder and schizoaffective disorder. A total of 300 Korean patients participated in the study. Among them, 39 patients with prominent negative symptoms were initially administered 15mg/day of aripiprazole for the first 2 weeks, and then treated with 10-30mg/day. The efficacy measures included the Positive and Negative Syndrome Scale(PANSS) total, positive and negative subscale scores, the Clinical Global Impression-Severity of Illness(CGI-S), and the CGI-Global improvements(CGI-I). Results：The significant improvements were observed in all 3 PANSS parameters ; total(-35.72 ; p＜.0001), positive subscale(-7.41 ; p＜.0001), and negative subscale scores(-11.56 ; p＜.0001). The difference between positive and negative subscale scores was significantly decreased from baseline to week 52. CGI-S was also decreased (-1.67 ; p＜.0001), and 41.03% of patients appeared to respond according to CGI-I. Conclusion：Aripiprazole may be as much efficacious against negative symptoms as positive symptoms in schizophrenia. This suggests the possibility clinicians can consider aripiprazole as a drug of choice in the chronic schizophrenic patients with prominent negative symptoms before trying switching other antipsychotics with clozapine.

참고문헌 (29)

  1. Saha S, "A systematic review of the prevalence of schizophrenia", PLoS Med, 2, pp.e141~ (2005)
  2. Bellack AS, "An analysis of social competence in schizophrenia", Br J Psychiatry, 156, pp.809~818 (1990)
  3. Stip E, "Novel antipsychotics:Issues and controversies.Typicality of atypical antipsychotics", J Psychiatry Neurosci, 25, pp.137~153 (2000)
  4. Kasper S, "Efficacy and safety of aripiprazole vs.haloperidol for long-term maintenance treatment following acute relapse of schizophrenia", Int J Neuropsychopharmacol, 6, pp.325~337 (2003)
  5. Jordan S, "The antipsychotic aripiprazole is a potent,partial agonist at the human 5-HT1A receptor", Eur J Pharmacol, 441, pp.137~140 (2002)
  6. Burris KD, "Aripiprazole,a novel antipsychotic,is a highaffinity partial agonist at human dopamine D2 receptors", J Pharmacol Exp Ther, 302, pp.381~389 (2002)
  7. butyloxy)-3,4-dihydro-2(1H)-quinolinone(OPC-14597),a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity, "J Pharmacol Exp Ther", 1995, 329~336
  8. Lawler CP, "Interactions of the novel anti natupsychotic aripiprazole(OPC-14597)with dopamine and serotonin receptor subtypes", Neuropsychopharmacology, 20, pp.612~627 (1999)
  9. Goldstein M, "Dopaminergic mechanisms in the pathogenesis of schizophrenia", FASEB J, 6, pp.2413~2421 (1992)
  10. Kane JM, "Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder", J.Clin Psychiatry, 63, pp.763~771 (2002)
  11. Potkin SG, "Aripiprazole,an antipsychotic with a novel mechanism of action,and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder", Arch Gen Psychiatry, 60, pp.681~690 (2003)
  12. Kane JM, "Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks", Schizophr Res, 95, pp.143~150 (2007)
  13. Pigott TA, "Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia:A placebocontrolled 26-week study", J Clin Psychiatry, 64, pp.1048~1056 (2003)
  14. Leucht S, "Second-generation versus firstgeneration antipsychotic drugs for schizophrenia:A meta-analysis", Lancet, 373, pp.31~41 (2009)
  15. Kwon JS, "APLUS study group.Long-term efficacy and safety of aripiprazole in patients with schizophrenia,schizophreniform disorder,or schizoaffective disorder:26-week prospective study", Psychiatry Clin Neurosci, 63, pp.73~81 (2009)
  16. Chan HY, "Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control:a randomized trial", J Clin Psychiatry, 68, pp.29~36 (2007)
  17. 박혜윤, "정신분열병 환자에서 52주간의 Aripiprazole 치료가 사회적 기능에 미치는 영향", 대한정신약물학회지, 19(5), pp.256~265 (2008), 대한정신약물학회
  18. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed" (2000), APA
  19. Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
  20. Anghelescu I, "Are new drugs for schizo phrenia better than old ones", Lancet, 373, pp.1249~ (2009)
  21. Ramaswamy S, "Aripiprazole possibly worsens psychosis", Int Clin Psychopharmacol, 19, pp.45~48 (2004)
  22. Pae CU, "Predictors of early worsening after switch to aripiprazole:a randomized,controlled,open-label study", Clin Drug Investig, 30, pp.187~193 (2010)
  23. Tandon R, "A prospective,multicenter,randomized,parallel-group,open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice:Broad Effectiveness Trial With Aripiprazole(BETA)", Schizophr Res, 84, pp.77~89 (2006)
  24. de Oliveira IR, "Aripiprazole for patients with schizophrenia and schizoaffective disorder:an open-label,randomized,study versus haloperidol", CNS Spectr, 14, pp.93~102 (2009)
  25. Bell M, "Object relations deficits in subtypes of schizophrenia", J Clin Psychol, 48, pp.433~444 (1992)
  26. Berman RM, "The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder:A multicenter,randomized,double-blind,placebo-controlled study", J Clin Psychiatry, 68, pp.843~853 (2007)
  27. Keck PE Jr, "Aripiprazole Study Group.Aripiprazole monotherapy for maintenance therapy in bipolar I disorder:A 100-week,doubleblind study versus placebo", J Clin Psychiatry, 68, pp.1480~1491 (2007)
  28. Lee HY, "Trial of aripiprazole in the treatment of first-episode schizophrenia", Psychiatry Clin. Neurosci., 64(1), pp.38~43 (2010)
  29. McGorry PD, "Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms", Arch Gen Psychiatry, 59, pp.921~928 (2002)

관련 논문AI추천

만성적 정신분열병 또는 분열정동장애를 가진 입원환자에서 Aripiprazole과 Haloperidol의 치료효과 및 안정성 비교：16주간의 임상적 연구의 결과김정기, 서영익, 장옥진대한생물치료정신의학회 · 생물치료정신의학2009 · 제15권 제2호조현병 환자에서 항정신병약물 유지치료 시 치료결과에 대한 연구나의현, 박은경, 배하현, 윤해주, 이종일대한조현병학회 · 대한조현병학회지2017 · 제20권 제2호높은 초조 또는 낮은 초조 증상을 경험하는 정신분열병 급성기 입원환자의 아리피프라졸 치료 효과신지현, 이광헌, 한영훈, 사공정규대한신경정신의학회 · 신경정신의학2009 · 제48권 제5호항정신병 약물의 병용요법을 사용 중인 환자들에서 아리피프라졸 장기 지속형 주사제의 효능김세훈, 박영민, 박태형, 변원탄, 서제영, 정일근, 주새한대한생물치료정신의학회 · 생물치료정신의학2024 · 제30권 제3호만성정신분열증 환자에 대한 리스페리돈 장기투여 2례강병조, 박순원대한생물치료정신의학회 · 생물치료정신의학1995 · 제1권 제2호일 종합병원에서 정신분열병과 분열정동장애를 진단받은 환자에서 항정신병약물의 1차 선택약물의 비율 및 1년 유지율에 관한 연구김정기, 서영익, 왕관수, 장옥진, 제호준, 조동환, 최성진대한생물치료정신의학회 · 생물치료정신의학2008 · 제14권 제1호

이 간행물의 다른 논문 (14건)

미래의 항우울제이민수, 사공정규pp. 153-163우리나라 외래치료명령제의 시행과 개선방향이기경, 이유진, 용효중, 나리지, 황태연, 김건우, 이종국, 홍진표pp. 164-175말기치매 환자의 완화의료전진숙pp. 176-181섬망 치료에 있어서 Quetiapine과 Risperidone의 효과 비교사공정규, 정성원pp. 182-188한국판-Gilliam 자폐증 평정척도-2(K-GARS-2) 표준화 연구진혜경, 윤혜주, 박진박pp. 189-194
원문 보기